Reagent
Recombinant Human IRN gamma,CYT-P01579
Click£º6919 Release date£º2020-7-23 Author£ºAdministrator Source£ºOriginal
Recombinant Human IRN gamma,CYT-P01579
Function
Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation (PubMed:16914093, PubMed:8666937).
Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation (PubMed:8349687).
Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription (PubMed:16914093).
Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits (PubMed:8666937).
In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading (PubMed:8163024).
Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference (PubMed:11112687).
Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL (PubMed:7729559).
Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity).By Similarity
Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation (PubMed:8349687).
Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription (PubMed:16914093).
Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits (PubMed:8666937).
In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading (PubMed:8163024).
Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference (PubMed:11112687).
Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL (PubMed:7729559).
Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity).By Similarity
|
Order Information |
|||||
|
Cat./REF. |
Size |
Price($£© |
Price(€) |
Price(£¤/CNY£© |
Price(£¤/JYP£© |
|
CYT-P01579 |
10ug |
$60.00 |
€ 72.00 |
£¤600.00 |
£¤11,940.00 |
|
CYT-P01579 |
100ug |
$247.50 |
€ 297.00 |
£¤2,475.00 |
£¤49,252.50 |
|
CYT-P01579 |
500ug |
$990.00 |
€ 1,188.00 |
£¤9,900.00 |
£¤197,010.00 |
On an article£ºRecombinant Human APP,CYT-P05067
Next article£ºRecombinant Human PDGF-BB,CYT-P09619
